Shilpa Medicare growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+19.6%+11.7%+9.7%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+37.1%+29.7%+139.0%
+54.4%+49.4%+1,914.4%
+210.8%+145.6%+198.1%
+54.7%+119.1%−1.9%
+11.9%+7.0%+6.6%
+9.6%+31.3%+1.4%
+158.9%−2.3%−40.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SHILPAMED₹935.60

Shilpa Medicare Ltd.

· Pharma & Health
₹ CrorePeersNATCOPHARMSPARCSTARRUBICONSUPRIYATHYROCAREVIYASHPARKHOSPSMcap ₹18,300 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+9.7+11.7+19.6—
EBITDA Growth—+139.0+29.7+37.1—
EBIT Growth—+1,914.4+49.4+54.4—
Net Income Growth—+198.1+145.6+210.8—
EPS Growth—-1.9+119.1+54.7—
Total Assets Growth—+6.6+7.0+11.9—
Total Equity Growth—+1.4+31.3+9.6—
Cash from Operations Growth—-40.2-2.3+158.9—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.